3.
Hahn EV and Gillespie EB. Sickle cell anemia: Report of a case greatly
improved by splenectomy; Experimental study of sickle cell formation. Arch.
Intern. Med. 39:223,1927.
4.
Scriver JB and Waugh TR. Studies on a case of sickle-cell anemia. Can.
Med. Assoc. J. 23:375,1930.
5.
Ham TH and Castle WB. Relation of increased hypotonic fragility and of
erythrostasis to mechanism of hemolysis in certain anemias Trans.
Assoc. Am. Physicians 55:127,1940.
6.
Sherman IJ. The sickling phenomenon, with special reference to the
differentiation of sickle cell anemia from sickle cell trait. Bull.
Johns Hopkins Hosp. 67: 309,1940.
7.
Watson J, Stahman AW and Bilello FP. The significance of the paucity of
sickled cells in newborn Negro infants. Am.
J Med. Sci. 215: 419, 1948.
8.
Pauling L, Itano H, Singer SJ and Wells IC. Sickle cell anemia: A
molecular disease. Science 110:543,1949.
9.
Ingram VM. A specific chemical difference between the globins of normal
human and sickle-cell anaemia haemoglobin. Nature 178:792,1956.
10.
Ingram VM. Gene mutations in human haemoglobin: The chemical difference
between normal and sickle cell haemoglobin. Nature 180:326,1957.
11.
Beadle GW and Tatum EL. Genetic control of biochemical reactions in Neurospora.
Proc. Natl. Acad. Sci. 27:499, 1941.
12.
Perutz MF. The Hemoglobin Molecule. Scientific American. Nov. , 1964.
13.
Perutz MF. The haemoglobin molecule. Proceedings of the Royal Society
of London-Series B: Biological Sciences 173:113, 1969.
14.
Perutz MF. Stereochemistry of cooperative effects in haemoglobin. Nature
228:726, 1970.
15.
Lawn RM, Fritsch EF, Parker RC, Blake G and Maniatis T. The isolation and
characterization of linked
d
- and
b
-globin genes from a cloned library of human DNA. Cell
15:1157,1978.
16.
Lauer J, Shen C-K J and Maniatis T. The chromosomal arrangement of human
a
-like globin genes: Sequence homology and
a
-globin gene deletions.
Cell 20:119,1980.
17.
Bunn F and Forget B. Hemoglobin:
Molecular, Genetic and Clinical Aspects. Philadelphia :W.B.Saunders Co.,
1986.
18.
Bunn HF, Noguchi CT, Hofrichter J, Schecter GP, Schecter AN and Eaton WA.
Molecular and cellular pathogenesis of hemoglobin SC disease. Proc.
Natl. Acad. Sci 79: 7527, 1982.
19.
Steinberg MH, Adams JG and Hendrix R. Sickle cell-beta-thalassemia: a
common phenocopy of sickle cell anemia. Journal
of the Mississippi State Medical Association 23: 319, 1982.
20.
Ringelhann B, Lewis RA, Lorkin PA, Kynoch PAM and Lehmann H. Sickle Cell
Haemoglobin D Punjab Disease: S from Ghana and D from England. Acta
Hemat. 38:324,1967.
21.
Monplaisir N, Merault G, Poyart C, Rhoda MD, Craescu CT, Vidaud M,
Galacteros F, Blouquit Y and Rosa J. Hemoglobin S Antilles: A variant with lower
solubility than hemoglobin S and producing sickle cell disease in heterozygotes.
Proc. Natl. Acad. Sci 83: 9363, 1986.
22.
Fleming AF. The presentation, management and prevention of crisis in
sickle cell disease in Africa [Review]. Blood
Reviews 3:18,1989.
23.
Scott RB and Castro O. Screening for sickle cell hemoglobinopathies. J
Am. Med. Assoc. 241:1145, 1979.
24.
Motulsky AG. Frequency of sickling disorders in U.S. blacks. New
Eng. J Med. 288:31, 1973.
25.
Dr. N Olivieri.
26.
Bookchin RM and Lew VL. Pathophysiology of sickle cell anemia [Review]. Hematology
/Oncology Clinics of North America 10:1241,1996.
27.
Embury SH, Hebbel RP, Mohandas N and Steinberg MH (eds). Sickle
Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press,
1994.
28.
Diggs LW. The crisis in
sickle cell anemia: Hematological studies. Am.
J Clin. Pathol. 26:1109,1956.
29.
Diggs LW. Sickle cell
crises. Am. J Clin. Pathol. 44:1,1965.
30.
Powars DR. Sickle cell anemia and major organ failure [Review]. Hemoglobin
14:573-98, 1990.
31.
Vichinsky E. Comprehensive care in sickle cell disease: its impact on
morbidity and mortality. Seminars in
Hematology 28:220, 1991.
32.
Sullivan LW. The risks of sickle cell trait: caution and common sense. New
Eng. J Med 317:830, 1987.
33.
Charache S. Fetal Hemoglobin, Sickling, and Sickle Cell Disease. Advances
in Pediatrics 37:1,1990.
34.
Adekile AD and Huisman THJ. Hb F in sickle cell anemia. Experientia
49:16,1993.
35. Steinberg M. The interactions of a -thalassemia with hemoglobinopathies [Review]. Hematology/Oncology Clinics of North America 5:453, 1991.
36.
Steinberg MH. Dreiling BJ. Clinical, hematologic and biosynthetic studies
in sickle cell-beta 0-thalassemia: a comparison with sickle cell anemia. Am.
J Hematol 1:35-44, 1976.
37.
Serjeant GR, Serjeant BE. Comparison of sickle cell beta o-thalassemia
and sickle cell beta +-thalassemia in black populations. Birth
Defects: Original Article Series. 18:223, 1982.
38.
Nagel RL and Fabry ME. The many pathophysiologies of sickle cell anemia
[Review]. Am. J Hematol. 20:195,1985.
39.
Charache S, Lubin B and Reid C. Management and therapy of sickle cell
disease. U.S Dept. Of Health and Human
Services, NIH Publ.No. 89-2117, 1989.
40.
Powars DR. Natural History of Sickle Cell Disease: The First Ten Years. Sem.
in Hematol. 12:267,1975.
41.
Barrett DH, Wisotzek IE, Abel GG et al. Assessment of psychosocial
functioning of patients with sickle cell disease. Southern Med. J. 81:745, 1988.
42.
Thomas AN, Pattison C and Serjeant GR. Causes of death in sickle cell
disease in Jamaica. Brit. Med. J
285:633,1982.
43.
Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, Pegelow
CH and Vickinsky E. Clinical events in the first decade in a cohort of infants
with sickle cell disease. Blood
86:776,1995.
44.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH and
Klug PP. Mortality in sickle cell disease: Life expectancy and risk factors for
early death. New Eng. J Med.
330:1639,1994.
45.
National Institute of Health Consensus
Development Conference Statement. Newborn screening for sickle cell disease and
other hemoglobinopathies. J Am. Med. Assoc.
258: 1205, 1987.
46.
Bunn FH. Pathogenesis
and Treatment of Sickle Cell Disease[Review]. New Eng. J Med. 337:762, 1997.
47.
Perutz MF. Hemoglobin Structure and Respiratory Transport. Scientific
American :92, 1978.
48.
Giardina B, Messana I, Scatena R and Castagnola M. The multiple functions
of hemoglobin[Review]. Critical Reviews in
Biochemistry and Molecular Biology 30:165,1995.
49.
Glanz J. Hemoglobin Reveals New Role as Blood
Pressure Regulator. Science
271:1670,1996.
50.
Bunn HF. Subunit
assembly of hemoglobin: An important determinant of hematologic phenotype. Blood
69:1,1987.
51.
Bunn HF and McDonald MJ.
Electrostatic interactions in the assembly of haemoglobin. Nature 306:498,1983.
52.
Nagel RL, Johnson J, Bookchin RM, Garel MC, Rosa J, Schiliro G, Wajcman
H, Labie D, Woo-Pen W and Castro O.
b
-Chain contact sites in the haemoglobin polymer. Nature 283:832,1980.
53.
Perutz MF and Mitchison JM. State of haemoglobin in sickle cell anemia. Nature
166:677,1950.
54.
Noguchi CT and Schecter AN. The intracellular polymerization of sickle
hemoglobin and its relevance to sickle cell disease[Review]. Blood
58:1057,1981.
55.
Bunn F and Forget B. Sickle Cell Disease- Molecular and Cellular
Pathogenesis. in Hemoglobin: Molecular,
Genetic and Clinical Aspects. (Philadelphia :W.B.Saunders Co.,
1986),p.453-501.
56.
SanBagio PL, Hofrichter J, Mozzarelli A, Henry ER and Eaton WA. Current
perspectives on the kinetics of hemoglobin S gelation. Ann.
New York Acad. Sci.565 :53, 1989.
57.
Finch JT, Perutz MF, Bertles JF and Dobler J. Structure of sickled
erythrocytes and of sickle-cell hemoglobin fibers. Proc. Natl. Acad. Sci. 70:718,1973.
58.
Wishner BC, Ward KB, Lattman EE and Love WE. Crystal structure of
sickle-cell deoxyhemoglobin at 5 Å resolution. J Mol. Biol. 98:179,1975.
59.
Padlan EA and Love WE. Refined crystal structure of deoxyhemoglobin S:I.
Refined least-squares refinement at 30 Å resolution. J Biol. Chem. 260:8272,1985.
60.
Padlan EA and Love WE. Refined crystal structure of deoxyhemoglobin S:II.
Molecular interactions in the crystal. J Biol. Chem. 260:8280,1985.
61.
Edelstein SJ. Molecular topology in crystals
and fibers of hemoglobin S. J Mol. Biol. 150:557,1981.
62.
Acquaye C, et al. Electron
microscopic studies of the intracellular polymerization of sickle hemoglobin. Blood
Cells 13 :1359,1988.
63.
Kaul DK, Fabry ME and Nagel RL. The pathophysiology of vascular
obstruction in the sickle syndromes [Review]. Blood Reviews 10:29,1996.
64.
Asakura T, Mattiello JA, Obata K, Asakura K, Reilly MP, Tomassini N,
Schwartz E and Ohene-Frempong K. Patially oxygenated sickled cells:
Sickle-shaped red cells found in circulating blood of patients with sickle cell
disease. Proc. Natl. Acad. Sci 91:
12589, 1994.
65.
Bertles JF and Milner PF. Irreversibly sickled erythrocytes: A
consequence of the heterogeneous distribution of hemoglobin types in sickle-cell
anaemia. J Clin. Invest. 47:1731,1968.
66.
Serjeant GR, Serjeant BE and Milner PF. The Irreversibly sickled cell; a
determinant of haemolysis in sickle-cell anaemia. Brit. J Haematol.
17:527,1969.
67.
Hofrichter J, Ross PD and Eaton WA. Kinetics and mechanism of
deoxyhemoglobin gelation-a new approach to understanding sickle cell disease. Proc.
Natl. Acad. Sci. 71:14864, 1974.
68.
Eaton WA, Hofrichter J, and Ross P.D. Delay time of gelation: A possible
determinant of clinical severity in sickle cell disease[Editorial]. Blood
47; 621, 1976.
69.
Eaton WA and Hofrichter J. Hemoglobin S Gelation and Sickle Cell Disease
[Review]. Blood 70:1245, 1987.
70.
Mozzarelli A, Hofrichter J and Eaton WA. Delay time of hemoglobin
polymerization prevents most cells from sickling in vivo. Science 237:500,
1987.
71.
Noguchi CT, Torchia DA and Schecter AN. Determination of deoxyhemoglobin
S polymer in sickle erythrocytes upon deoxygenation. Proc.
Natl. Acad. Sci. 77: 5487, 1980.
72.
Brittenham GM, Schecter AN and Noguchi CT. Hemoglobin S polymerization:
Primary determinant of the hemolytic and clinical severity of the sickling
syndromes. Blood 65:183, 1985.
73.
Noguchi CT, Rodgers GP and Schecter AN. Intracellular polymerization:
Disease severity and therapeutic predictions. Ann.
New York Acad. Sci.565 :75,1989.
74.
Hiruma H, Noguchi CT, Uyesaka N, Hasegawa S, Blanchette-Mackie EJ,
Schecter A and Rodgers GP. Sickle cell rheology is determined by polymer
fraction-not cell morphology. Am. J
Hematol 48:19, 1995.
75.
Hebbel RP.Beyond Hemoglobin Polymerization: The red cell membrane and
sickle cell disease pathophysiology [Review]. Blood 77:214,1991.
76.
Lux SE, John KM and Karnovsky MJ. Irreversible deformation of the
spectrin-actin lattice in irreversibly sickled cells. J Clin. Invest. 58: 955, 1976.
77.
Jensen WN, Bromberg PA and Barefield K. Membrane deformation: A cause of
irreversibly sickled cells (ISC). Clin.
Res. 17:464, 1969.
78.
McCurdy PR, Sherman AD. Irreversibly sickled cells and red cell survival
in sickle cell anemia. Am J Med
64:253,1978.
79.
Zago MA and Bottura C. Splenic function in sickle cell disease. Clinical
Science 65: 297,1983.
80.
Connor J, Pak CC and Schroit AJ. Exposure of phosphatidylserine in the
outer leaflet of human red blood cells. Relationship to cell density, cell age,
and clearance by mononuclear cells. J
Biol. Chem. 269:2399, 1994.
81.
Grasso JA, Sullivan AL and Sullivan LW. Ultrastructural studies of the
bone marrow in sickle cell anaemia. Brit.
J Haematol. 31:135, 1975.
82.
Ashby W. The determination of the length of life of transfused blood
corpuscles in man. J Exp. Med. 29:
267, 1919.
83.
Ballas SK and Mohandas N. Pathophysiology of vaso-occlusion [Review]. Hematology
/Oncology Clinics of North America 10:1221,1996.
84.
Schwartz RS, Musto S, Fabry ME and Nagel RL. Two distinct pathways
mediate the formation of intermediate density cells and hyperdense cells from
normal density sickle red blood cells. Blood
92:4844, 1998.
85.
Ballas SK, Larnar J, Smith ED, Surrey S,
Schwartz E and Rappaport EF. The xyerocytosis of Hb SC disease. Blood
69:124,1987.
86.
Sutera SP, et al. Rheoscopic
investigation of red cell deformability in sickle cell anemia. ISA
Transactions 25: 1, 1986.
87.
Clark MR, Mohandas N and
Shohet SB. Deformability of oxygenated irreversibly sickled cells. J
Clin. Invest. 65:189, 1980.
88.
Kuypers FA. Red cell membrane damage. J Heart Valve Disease 7:387, 1998.
89.
Nash GB, Johnson CS and Meiselman H. Mechanical properties of oxygenated
red blood cells in sickle cell (Hb SS) disease. Blood 63:73,1984.
90.
Hoover R, Rubin R, Wise G and Warren R. Adhesion of normal and sickle
erythrocytes to endothelial monolayer cultures. Blood 54: 872, 1979.
91.
Hebbel RP et al. Abnormal Adherence of Sickle Erythrocytes to Cultured
Vascular Endothelium. J Clin. Invest.
65: 155, 1980.
92.
Hebbel RP et al. Erythrocyte Adherence To Endothelium In Sickle-Cell
Anemia. New Eng. J Med. 302: 993,
1980.
93.
Hebbel RP and Mohandas N.Sickle cell adherence. in Embury SH, Hebbel RP,
Mohandas N and Steinberg MH (eds). Sickle
Cell Disease: Basic Principles and Clinical Practice. (New York: Raven
Press, 1994),p.217-230.
94.
Ballas SK et al. Rheological Predictors of the
Severity of the Painful Sickle cell Crisis. Blood
72: 1217, 1988.
95.
Lande WM et al. The
Incidence of Painful crisis in Homozygous Sickle Cell Disease: Correlation With
Red Cell Deformability. Blood 72:
2056, 1988.
96.
Powars D, Chan LS and Schroeder WA. The variable expression of sickle
cell disease is genetically determined. Semin. in Hematol. 27:361,1990.
97.
Nagel RL. Sickle cell anemia is a multigene disease: Sickle painful
crises, a case in point. [Editorial]. Am.
J Hematol. 42:96,1993.
98.
Summers KM. Relationahip between genotype and phenotype in monogenic
diseases: relevance to polygenic diseases [Review]. Human Mutation 7:283, 1996.
99.
Chang YC, Smith KD, Moore RD, Serjeant GR and Dover GJ. An analysis of
fetal hemoglobin variation in sickle cell disease: The relative contributions of
the X-linked factor,
b
-globin haplotypes,
a
-globin gene number, gender, and age. Blood
85:1111, 1995.
100.Embury SH and Steinberg
MH. Genetic Modulators of Disease. in Sickle
cell Disease: Basic principles and Clinical Practice. Embury SH, Hebbel RP,
Mohandas N and Steinberg MH (eds.). (New York:Raven Press, Ltd.,1994),
p.279-298.
101.Powars DR, Chan L and
Schroeder WA. The influence of fetal hemoglobin on the clinical expression of
sickle cell anemia [Review]. Ann. New York Acad. Sci. 565 :262,1989.
102.Dover GJ, Smith KD, Chang
YC, Purvis S, Mays A, Meyers DA, Sheils C and Serjeant GR. Fetal hemoglobin
levels in sickle cell disease and normal individuals are partially controlled by
an X-linked gene located at Xp22.2. Blood
80:816,1992.
103.Weatherall DJ and Clegg JB. The Thalassemia Syndromes. Oxford,UK: Blackwell, 1981.
104.Higgs DR. The thalassemia
syndromes[Review]. Quartely J Medicine 86: 559, 1993.
105.Schrier SL. Thalassemia:
Pathophysiology of red cell changes[Review]. Ann.
Rev. Med 45:211,1994.
106.Serjeant G, Sommereaux
A-M, Mason K and Serjeant B. Comapison of sickle-cell-
b
0 -thalassemia with homozygous sickle cell
disease. Br. J. Haematol. 41:83, 1979.
107.Driscoll MC, Dobkin CS
and Alter BP.
g
d
b
-Thalassemia due to a de
novo mutation deleting the 5
¢
b
-globin gene activation-region hypersensitive sites. Proc.
Natl. Acad. Sci. 86:747-, 1989.
108.Bailey S, Higgs DR,
Morris J and Serjeant GR. Is the painful crisis of sickle-cell disease due to
sickling
?
Lancet 337:735,1991.
109.Schrier SL, Rachmilewitz
E and Mohandas N. Cellular and membrane properties of alpha and beta thalassemic
erythrocytes are different: Implication for differences in clincal
manifestations. Blood 74:2194,1989.
110.Dozy AM, Kan YW, Embury
SH, Mentzer WC, Wang WC, Lubin B, Davis Jr. JR and Koenig HM.
a
-Globin gene organization in blacks precludes the severe form
of
a
-thalassemia. Nature 280:605, 1979.
111.Higgs DR, Aldridge BE,
Lamb J, Clegg JB, Weatherall DJ, Hayes RJ, Grandison Y, Lowrie Y, Mason K,
Serjeant BE and Serjeant GR. The interaction of alpha-thalassemia and homozygous
sickle-cell disease. N Eng. J Med. 306:1441,
1982.
112.Embury SH, Dozy AM,
Miller J, Davis Jr. JR, Kleman KM, Preisler H, Vichinsky E, Lande WN, Lubin BH,
Kan YW and Mentzer WC. Concurrent Sickle-cell anemia and
a
-thalassemia: Effect on severity of anemia. N
Eng. J Med. 306:270, 1982.
113.Embury SH, Clark MR,
Monroy G and Mohandas N. Concurrent sickle cell anemia and
a
-thalassemia. J
Clin. Invest. 73:116, 1983.
114.DeCelaer K, Higgs DR,
Hayes RJ, Serjeant BE and Serjeant GR.
a
-Thalassemia reduces the hemolytic rate in homozygous sickle
cell disease. N Eng. J
Med. 309:189, 1983.
115.Mears JG, Lachman HM,
Labie D and Nagel RL. Alpha thalassemia is related to prolonged survival in
sickle cell anemia. Blood 62:286,1983.
116.Steinberg MH, Coleman MB,
Adams III JG, Hartmann RC, Saba H and Anagnou NP. A new gene deletion in the
a
-like globin gene cluster as the molecular basis for the rare
a
-thalassemia-1 (--/
a
a
) in Blacks: HbH disease in sickle cell trait. Blood 67:469,1986.
117.Gill SJ, Benedict RC,
Fall L, Spokane R and Wyman J. Oxygen binding to sickle hemoglobin.
J Mol. Biol. 130:175,1979.
118.Seakins M, Gibbs WN,
Milner PF, and Bertles JF. Erythrocyte Hb-S concentration: An important factor
in the low oxygen affinity of blood in sickle cell anemia. J
Clin. Invest. 52:422,1973.
119.Charache S, Grisolia S,
Fielder AJ and Hellegers AE. Effect of 2,3-diphosphoglycerate on oxygen affinity
of blood in sickle cell anemia. J Clin.
Invest. 49:806,1970.
120.Torrance J, Jacobs P,
Restrepo A, EscHb Ach J, Lenfant C and Finch CA. Intraerythrocytic adaptation to
anemia. New Eng J Med 283:165,1970.
121.DeSimone
J. Heller P. Biel SI. Stimulation of fetal hemoglobin
synthesis following stress erythropoiesis: Fetal hemoglobin and stress
erythropoiesis. pp. 139-51. In: Stamatoyannopoulos G, Niehuis AW, (eds.) Cellular
and molecular regulation of hemoglobin switching. New York : Grune
& Stratton, 1979.
122.Croizat H. Nagel RL.
Circulating cytokines response and the level of erythropoiesis in sickle cell
anemia. Am. J Hematol. 60:105-15,
1999.
123.Platt OS, Rosenstock W
and Espeland MA. Influence of sickle hemoglobinopathies on growth and
development. New Eng. J Med. 311:7,1984.
124.Singhal A, Morris J,
Thomas P, Dover G, Higgs D and Serjeant G. Factors affecting prepubertal growth
in homozygous sickle cell disease. Arch.
Disease in Childhood 74:502,1996.
125.Davies SC. Blood
transfusion in sickle cell disease [Review]. Current
Opinion in Hematology 3:485, 1996.
126.Noguchi CT, Rodgers GP,
Serjeant G and Schecter AN. Levels of fetal hemoglobin necessary for treatment
of sickle cell disease. New Eng. J Med
318:96,1988.
127.Walters MC, Patience M,
Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K,
Bernaudin F, Matthews DC, Storb R, Sullivan KM. Bone marrow transplantation for
sickle cell disease. New Eng. J Med.
335:369, 1996.
128.Vermylen C and Cornu G.
Bone marrow transplantation for sickle cell anemia [Review]. Current
Opinion in Hematology 3:163, 1996.
129.Bowman JE. Is a national program to prevent sickle cell disease possible? Am. J Ped. Hem. Onc. 5:367, 1983.